Tumor Uptake of PEGylated Diabody: Balancing between Antibody Size and Systemic Clearance is organized by KNect365 Life Sciences and will be held on Apr 23, 2018.
This conference is downloadable resources with the latest science, technologies, and partners to accelerate next-generation antibodies toward commercial success.
Session Description :
Antibody tumor targeting is a complex process involving many factors such as antibody size, distribution and clearance in the plasma. Antibody fragments with optimal profile balanced between size and systemic clearance hold potential for diagnostic and therapeutic applications of tumor malignancies. This talk focuses on the investigation of the correlation of hydrodynamic size, pharmacokinetic parameters, and tumor uptake of PEGylated diabody.
Additional details will be posted as soon as they are available.